PKDCC KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 32 bp deletion in exon1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 32 bp deletion in exon1.
Alternative names
FLJ18197, Hypothetical protein BC007901, Hypothetical protein LOC91461, MGC125960, PKDCC_HUMAN, Protein kinase domain containing cytoplasmic, Protein kinase domain containing, cytoplasmic homolog (mouse), Protein kinase domain-containing protein, cytoplasmic, Protein kinase-like protein SgK493, SGK493, Sugen kinase 493, Vertebrate lonesome kinase
What's included?
Recommended products
PKDCC KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 32 bp deletion in exon1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 32 bp deletion in exon1.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- PKDCC
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
VLK also known as V-set and transmembrane domain-containing protein E is a serine/threonine kinase with a molecular mass of approximately 54 kDa. It localizes mainly in the Golgi apparatus. Scientists detect VLK expression across various tissues including the heart testis and liver. This kinase executes post-translational modifications by phosphorylating intracellular proteins which can modulate their functions and interactions.
- Biological function summary
VLK kinase activity impacts protein folding and trafficking within the Golgi apparatus. VLK associates with protein complexes involved in secretory pathways assisting cellular functions like protein secretion and cell surface expression. Research indicates that it contributes significantly to maintaining cellular homeostasis by ensuring proper protein maturation.
- Pathways
VLK plays a role in the secretory pathway which is essential for the transport and delivery of proteins and lipids throughout the cell. It shows interactions with proteins like ABCD3 and VCP that are pivotal in vesicular transport and protein quality control. VLK also participates in the RAS signaling pathway linking it to cell growth and differentiation by affecting downstream targets.
- Associated diseases and disorders
Recent studies highlight VLK's involvement with neurodegenerative diseases and cancer. Altered VLK activity correlates with conditions such as Alzheimer's disease where phosphorylation imbalances disrupt neuron function. In cancer VLK is overexpressed leading to misregulated cell proliferation. Connections to proteins like tau and LATS1 further demonstrate VLK's relevance in these diseases influencing both progression and therapeutic targeting.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Sanger Sequencing - Human PKDCC (VLK) knockout HeLa cell lysate (ab259043)
Homozygous: 32 bp deletion in exon1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com